Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Larry Dean
Following concerns initially raised at the 2006 ESC meeting in Barcelona that suggested an increased incidence of stent thrombosis, much additional evaluation of patients receiving drug eluting stents (DES) has occurred. Insights into the clinical, technical and pharmacologic aspects of the issue lead to identification of at risk populations, for example diabetic patients. Intravascular ultrasound and OCT studies gave further insight into appropriate stent sizing and incomplete stent apposition which contribute to stent thrombosis in general but in particular to DES. Long term studies confirmed that DES do not re-endothelialise at the same rate as bare metal stents placing patients at risk for very late events. Along with a better understanding of the clinical and technical aspects of patients at risk for thrombosis additional, more potent antiplatelet agents have also been developed which have been shown to be more effective in reducing thrombosis. In addition, new insights into the pharmacology of the drugs have occurred, particularly an understanding of genetic differences in the metabolism of these medications. This has been in parallel with improvements in stent design and the development of different antiproliferative drugs. While stent thrombosis remains a concern all of this has led to DES thrombosis rates that are in general less than 1%, which represents a very significant improvement in the occurrence of this sometimes catastrophic event.
Drug-eluting stent thrombosis in 2011: still an issue?
© 2017 European Society of Cardiology. All rights reserved